<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: KRAS mutation is a negative predictive factor for treatment with anti-epidermal growth factor receptor antibody in <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>KRAS mutation analysis is usually performed on <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> tissue because metastatic tissue is often not available </plain></SENT>
<SENT sid="2" pm="."><plain>However, controversial data are available on the concordance of test results between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> and corresponding <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>We assessed the concordance of KRAS mutation status in a study of 305 primary <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumours</z:e> and their corresponding <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Patients with histologically confirmed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> who underwent surgical resection of the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> and biopsy or surgical resection of the corresponding <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastasis</z:e> were included </plain></SENT>
<SENT sid="5" pm="."><plain>KRAS mutation analysis was performed for codons 12 and 13 </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: KRAS mutation was detected in 108 out of 305 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> (35.4%) </plain></SENT>
<SENT sid="7" pm="."><plain>In 11 cases (3.6%), we found a discordance between <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> and <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>: 5 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> had a KRAS mutation with a <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, 1 primary <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> was <z:mp ids='MP_0002169'>wild type</z:mp> with a KRAS mutation in the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e>, and in 5 cases the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumour</z:e> and the <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> had a different KRAS mutation </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSION: We observed a high concordance of KRAS mutation status of 96.4% (95% CI 93.6-98.2%) between primary <z:e sem="disease" ids="C0009404" disease_type="Neoplastic Process" abbrv="">colorectal tumours</z:e> and their corresponding <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>In only six patients (2.0%; 95% CI 0.7-4.2%), the discordance was clinically relevant </plain></SENT>
<SENT sid="10" pm="."><plain>In this largest and most homogenous study to date, we conclude that both <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumours</z:e> and <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> can be used for KRAS mutation analysis </plain></SENT>
</text></document>